Acquisition Announced

Eli Lilly acquisition of Calytrix Bio

US$1.5bn consideration

Announced 2026 (approx.)

Advisers

Calytrix Bio

Target

Financial adviser

Eli Lilly

Acquirer

Not disclosed

Target
Calytrix Bio
Acquirer
Eli Lilly
Buyer based in
United States
Sector
Biotech

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.